Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2021-05-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于参加2021年云南辖区上市公司投资者集体接待日的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (610 characters) about the company's participation in an investor collective reception day event organized by a regional stock association. It mentions the date and time of the event and the company representatives who will attend. There is no financial data, no detailed report, no voting results, no management changes, or other regulatory filings. The document is an announcement of an investor event, not a report or transcript. Given the nature and length, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2021-05-13 Chinese
昆药集团监事会关于公司2021年限制性股票激励计划激励对象名单（截止授予日）的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the verification of the list of incentive recipients under the company's 2021 restricted stock incentive plan. It discusses compliance with laws and regulations regarding the eligibility of incentive recipients and confirms the granting of restricted stock to certain individuals. There is no financial data, no report of financial results, no announcement of voting results, no management or board changes, no legal proceedings, no capital or financing update, and no mention of a shareholder meeting or proxy materials. The document is a regulatory compliance statement related to a stock incentive plan, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a formal regulatory filing related to corporate governance and compliance but does not constitute a governance report or remuneration report per se. Given the nature and length, it best fits under Regulatory Filings (RNS) as a compliance document regarding the stock incentive plan.
2021-05-10 Chinese
昆药集团关于向激励对象授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the granting of restricted stock to incentive recipients. It details the number of shares granted, the grant price, the conditions for granting, the list of recipients, and the legal opinions confirming the legitimacy of the grant. The document is focused on equity incentive plans and stock grants to management and employees, which is a capital structure and financing activity. It is not a full financial report, audit report, or earnings release. It is not a regulatory filing or announcement of a report publication. The content fits best under Capital/Financing Update (CAP) as it relates to stock-based compensation and equity grants, which affect the company's capital structure and financing.
2021-05-10 Chinese
昆药集团2021年限制性股票激励计划激励对象名单（截止授予日）
Director's Dealing Classification · 95% confidence The document is a list of recipients of a restricted stock incentive plan for 2021, detailing the number of shares granted to each executive and their proportion of total shares. It focuses on stock incentives granted to company executives and board members. This type of document is related to insider share transactions or executive compensation through stock awards. It is not a full financial report, earnings release, or regulatory filing about financial results. It is also not a general announcement or proxy solicitation. The closest specific category is Director's Dealing (DIRS), which covers personal share transactions by company directors and executives, including stock incentives. The document length is short and focused on share grants to insiders, fitting DIRS best.
2021-05-10 Chinese
北京德恒（昆明）律师事务所关于昆药集团2021年限制性股票激励计划授予相关事项的法律意见
Regulatory Filings
2021-05-10 Chinese
昆药集团九届四十次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the company's 40th board meeting of the 9th session, including approval of a restricted stock grant and participation in a minority equity auction of a subsidiary. The text includes voting results and references to related announcements but does not contain full financial statements or detailed financial analysis. It is a formal announcement of board decisions rather than a full management report or financial filing. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or regulatory filing.
2021-05-10 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.